Syngene International Limited (BOM:539268)
613.70
+2.85 (0.47%)
At close: May 9, 2025
Syngene International Revenue
In the fiscal year ending March 31, 2025, Syngene International had annual revenue of 36.42B INR with 4.41% growth. Syngene International had revenue of 10.18B in the quarter ending March 31, 2025, with 11.03% growth.
Revenue
36.42B
Revenue Growth
+4.41%
P/S Ratio
6.94
Revenue / Employee
5.60M
Employees
6,510
Market Cap
252.84B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 36.42B | 1.54B | 4.41% |
Mar 31, 2024 | 34.89B | 2.96B | 9.26% |
Mar 31, 2023 | 31.93B | 5.89B | 22.61% |
Mar 31, 2022 | 26.04B | 4.20B | 19.22% |
Mar 31, 2021 | 21.84B | 1.72B | 8.57% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,646.93B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,429.39B |
Infosys | 1,647.16B |
Bajaj Finance | 369.88B |
Syngene International News
- 20 days ago - Why are Syngene shares down 10% despite Q4 net profit jumping 2.8% YoY? - Business Upturn
- 20 days ago - Syngene International shares hit lower circuit crashing to 10% today after Q4 results - Business Upturn
- 2 months ago - Syngene International shares down 2.50% after USFDA issues Form 483 with five observations - Business Upturn
- 2 months ago - Suven Pharmaceuticals shares surge 12% as Macquarie initiates ‘Outperform’ rating with target price of Rs 1,500, estimating 29.9% upside potential - Business Upturn
- 3 months ago - Macquarie initiates Outperform call on Syngene International, Suven Pharma, Divi’s Lab, Blue Jet Healthcare - Business Upturn
- 3 months ago - Syngene International appoints Peter Bains as the CEO Designate of the company - Business Upturn
- 3 months ago - Syngene International shares fall nearly 6% on weak FY25 guidance and demand recovery delay - Business Upturn
- 5 months ago - Syngene shares surge after 2% equity worth Rs 706 crore changes hands in block deal - Business Upturn